Therefore, transgenic expression of IL-15 seemed like an appealing strategy to enhance CAR-T cell effector function, by enhancing proliferation and persistence of CAR-T cells in the TME and has been used in preclinical models of acute myeloid leukemia (AML), melanoma, glioblastoma or neuroblastoma (261–265, 273). This evidence concerns the gene IL15 and melanoma.